Page last updated: 2024-11-05

troglitazone and Heart Defects, Congenital

troglitazone has been researched along with Heart Defects, Congenital in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.

Research Excerpts

ExcerptRelevanceReference
"There is evidence that one of the key type 2 diabetes (T2D) loci identified by GWAS exerts its influence early on in life through its impact on pediatric BMI."1.38Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23. ( Aziz, AR; Deliard, S; Grant, SF; Zhao, J, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhao, J1
Deliard, S1
Aziz, AR1
Grant, SF1

Other Studies

1 other study available for troglitazone and Heart Defects, Congenital

ArticleYear
Expression analyses of the genes harbored by the type 2 diabetes and pediatric BMI associated locus on 10q23.
    BMC medical genetics, 2012, Sep-24, Volume: 13

    Topics: Adipocytes; Adipogenesis; Arrhythmias, Cardiac; Body Mass Index; Cell Line; Chromans; Chromosomes, H

2012